Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Mitomycin C plus vindesine or cisplatin plus epirubicin in previously treated patients with symptomatic advanced non-small-cell lung cancer

Summary

A total of 40 previously treated patients with symptomatic advanced non-small-cell lung cancer (NSCLC) were subjected to second-line chemotherapy with mitomycin C plus vindesine (MV) or cisplatin plus epirubicin (PE). The 12 patients treated with the MV regimen showed no objective response (OR) or symptom palliation. In the 28 patients who received the PE regimen, we obtained a 25% partial response rate, with amelioration of tumor-related symptoms occurring in 35.7% of cases and improvement in the performance status being noted in 25% of subjects. Both regimens were well tolerated. These data show that the administration of cisplatin-based secondline chemotherapy to patients with symptomatic advanced NSCLC may be useful.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Albain KS, Bitrain JD, Golomb HM, Hoffman PC, Demeester TR, Skosey C, Noble S, Blough RR (1984) Trial of vindesine, etoposide and cisplatin in patients with previously treated, advanced stage, non-small-cell bronchogenic carcinoma. Cancer Treat Rep 68: 413–415

  2. 2.

    Carmichael J, Gregor A, Cornbleet MA (1985) Cisplatin and vindesine in combination in the treatment of non small cell lung cancer. Eur J Cancer Clin Oncol 21: 811–814

  3. 3.

    Eagan RT, Frytan S, Richardson RL, Creagan ET, Nichols WC (1986) Phase II study of the three-drug combination of mitomycin C, CCNU and methotrexate (MCM) in advanced non-small cell lung cancer. Am J Clin Oncol 9: 67–70

  4. 4.

    Ganz PA, Figlin RA, Haskell CM, La Soto N, Siau J (1989) Supportive care versus supportive care and combination chemotherapy in metastatic non-small cell lung cancer. Cancer 63: 1271–1278

  5. 5.

    Gralla RJ, Kris MG, Potanovich LM, Marus LA, Heelan RT (1989) Enhancing the safety and efficacy of the MVP regimen (mitomycin+vinblastine+cisplatin) in 100 patients with inoperable non small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 8: 227

  6. 6.

    Gridelli C, Pepe R, Palmeri S, Iacobelli S, Gentile M, Gebbia V, Garufi C, Airoma G, Palmieri G, Russo A, Incoronato P, De Placido S, Perrone F, Basilico L, Rausa L, Ferrante G, Bianco AR (1991) Phase II study of mitomycin C, etoposide and vindesine in metastatic stage IV non-small-cell lung cancer. Cancer Chemother Pharmacol 28: 405–407

  7. 7.

    Klastersky J (1986) Therapy with cisplatin and etoposide for non small cell lung cancer. Semin Oncol 13 [Suppl 3]: 104–114

  8. 8.

    Klastersky J, Sculier JP, Mommen P, Ravez P, Libert P, Vandermoten G, Belquart D, Schmerber J (1985) Combination chemotherapy with mitomycin C and vindesine in the treatment of non small cell lung cancer (NSCLC). Proc Am Assoc Cancer Res 26: 153

  9. 9.

    Kris MG, Gralla RJ, Kelsen DP (1982) Trial of vindesine plus mitomycin in stage III non small cell lung cancer. An active regimen for out-patient treatment. Cancer Treat Rep 66: 1291–1297

  10. 10.

    Kris MG, Gralla RJ, Kalman LA, Kelsen DP, Casper ES, Burke MT, Groshen S, Cibas IR, Bagin R, Heelan RT (1985) Randomized trial comparing vindesine plus cisplatin with vinblastine plus cisplatin in patients with non small cell lung cancer with a analysis of methods of response assessment. Cancer Treat Rep 69: 387–395

  11. 11.

    Kris MG, Gralla RJ, Wertheim MS, Kelsen DP, O'Connell JP, Burke MT, Fiore JJ, Cibas IR, Heelen RT (1986) Trial of the combination of mitomycin, vindesine and cisplatin in patients with advanced non small cell lung cancer. Cancer Treat Rep 70: 1091–1096

  12. 12.

    Luedke DW, Luedke SL, Martalo A, Querenberry P, Birch R, Schlueter J, Hake J, Logan T (1986) Vindesine and mitomycin in the treatment of advanced non small cell lung cancer: a Southern Cancer Group trial. Cancer Treat Rep 70: 651–653

  13. 13.

    Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207–214

  14. 14.

    Rapp E, Peter JL, Willan A, Cormier Y, Murray N, Evans WK, Hodson DI, Clark DA, Feld R, Arnola AM, Ayoub JI, Wilson KS, Latreille J, Wierzbichi RF, Hill DP (1988) Chemotherapy can prolong survival in patients with advanced non-small cell lung cancer. Report of a Canadian multicenter randomized trial. J Clin Oncol 6: 633–641

  15. 15.

    Woods RL, Williams CJ, Levi J, Bell D, Byrne M, Kerestes ZL (1990) A randomized trial of cisplatin and vindesine versus supportive care only in advanced non-small cell lung cancer. Br J Cancer 61: 608–611

Download references

Author information

Correspondence to Cesare Gridelli.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Gridelli, C., Airoma, G., Incoronato, P. et al. Mitomycin C plus vindesine or cisplatin plus epirubicin in previously treated patients with symptomatic advanced non-small-cell lung cancer. Cancer Chemother. Pharmacol. 30, 212–214 (1992). https://doi.org/10.1007/BF00686314

Download citation

Keywords

  • Lung Cancer
  • Cancer Research
  • Partial Response
  • Objective Response
  • Mitomycin